Skip to content

Carteolol compared with timolol external smear in the treatment of capillary hemangioma

Carteolol compared with timolol external smear in the treatment of capillary hemangioma

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018869
Enrollment
Unknown
Registered
2018-10-14
Start date
2018-10-01
Completion date
Unknown
Last updated
2018-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Capillary hemangioma

Interventions

Group 1:External application of Carteolol
Group 2:External application of Timolol

Sponsors

The Third Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 1 Years

Inclusion criteria

Inclusion criteria: 1. before treatment, it was diagnosed as capillary hemangioma; 2. proliferative hemangioma aged 0-1 years; 3. superficial hemangioma: lesion thickness < 0.5cm; 4. the largest diameter of tumor was less than 5cm; 5. there were no symptoms such as ulceration and infection on the surface of tumor; 6. The family members of the patients are willing to cooperate with the treatment actively and are willing to go back to the doctor within the prescribed time to ensure the completion of the treatment.

Exclusion criteria

Exclusion criteria: 1. allergic to Kati Carol and / or timolol; 2. there are primary diseases in important organs; 3. There are other contraindications for treatment, such as hypothyroidism, bronchial asthma, sinus bradycardia, second degree and above atrioventricular block, etc.; 4. failing to sign informed consent or fail to complete the examination; 5. other reasons may not be suitable for researchers.

Design outcomes

Primary

MeasureTime frame
Tumor size;

Countries

China

Contacts

Public ContactJunbo Qiao

The Third Affiliated Hospital of Zhengzhou University

junboqiao@sina.com+86 13939029769

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026